Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Pipeline Review, H2 2018
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Pipeline Review, H2 2018
SUMMARY
According to the recently published report 'Hepatocyte Growth Factor - Pipeline Review, H2 2018'; Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) pipeline Target constitutes close to 14 molecules.
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Hepatocyte growth factor (HGF) is a paracrine cellular growth and morphogenic factor secreted by mesenchymal cells and stimulates epithelial cell proliferation, motility, morphogenesis and angiogenesis in various organs via tyrosine phosphorylation of its receptor. It has a major role in embryonic organ development, specifically in myogenesis, in adult organ regeneration and in wound healing. In addition, HGF exerts protective effects on epithelial and non-epithelial organs (including the heart and brain) via anti-apoptotic and anti-inflammatory signals.
The report 'Hepatocyte Growth Factor - Pipeline Review, H2 2018' outlays comprehensive information on the Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 4, 2, 3 and 3 respectively. Report covers products from therapy areas Oncology, Central Nervous System, Cardiovascular, Dermatology, Genito Urinary System And Sex Hormones, Hematological Disorders and Metabolic Disorders which include indications Amyotrophic Lateral Sclerosis, Critical Limb Ischemia, Glioblastoma Multiforme (GBM), Non-Small Cell Lung Cancer, Alzheimer's Disease, Gastric Cancer, Melanoma, Myocardial Infarction, Ovarian Cancer, Pancreatic Cancer, Peripheral Arterial Disease (PAD)/Peripheral Vascular Disease (PVD), Acute Renal Failure (ARF) (Acute Kidney Injury), Acute Spinal Cord Injury, Advanced Malignancy, Angina (Angina Pectoris), Arteriosclerosis, Breast Cancer, Cervical Cancer, Colon Cancer, Colorectal Cancer, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Dementia, Diabetic Ischemic Foot Ulcers, Diabetic Peripheral Neuropathy, Gallbladder Cancer, Head And Neck Cancer, Hepatocellular Carcinoma, Kidney Cancer (Renal Cell Cancer), Leiomyosarcoma, Liver Cancer, Lung Cancer, Lymphedema, Lymphoma, Metastatic Cancer, Nasopharyngeal Cancer, Parkinson's Disease, Post-Operative Pain, Prostate Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Scar and Thromboangiitis obliterans (Buerger disease).
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'Hepatocyte Growth Factor - Pipeline Review, H2 2018'; Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) pipeline Target constitutes close to 14 molecules.
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Hepatocyte growth factor (HGF) is a paracrine cellular growth and morphogenic factor secreted by mesenchymal cells and stimulates epithelial cell proliferation, motility, morphogenesis and angiogenesis in various organs via tyrosine phosphorylation of its receptor. It has a major role in embryonic organ development, specifically in myogenesis, in adult organ regeneration and in wound healing. In addition, HGF exerts protective effects on epithelial and non-epithelial organs (including the heart and brain) via anti-apoptotic and anti-inflammatory signals.
The report 'Hepatocyte Growth Factor - Pipeline Review, H2 2018' outlays comprehensive information on the Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 4, 2, 3 and 3 respectively. Report covers products from therapy areas Oncology, Central Nervous System, Cardiovascular, Dermatology, Genito Urinary System And Sex Hormones, Hematological Disorders and Metabolic Disorders which include indications Amyotrophic Lateral Sclerosis, Critical Limb Ischemia, Glioblastoma Multiforme (GBM), Non-Small Cell Lung Cancer, Alzheimer's Disease, Gastric Cancer, Melanoma, Myocardial Infarction, Ovarian Cancer, Pancreatic Cancer, Peripheral Arterial Disease (PAD)/Peripheral Vascular Disease (PVD), Acute Renal Failure (ARF) (Acute Kidney Injury), Acute Spinal Cord Injury, Advanced Malignancy, Angina (Angina Pectoris), Arteriosclerosis, Breast Cancer, Cervical Cancer, Colon Cancer, Colorectal Cancer, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Dementia, Diabetic Ischemic Foot Ulcers, Diabetic Peripheral Neuropathy, Gallbladder Cancer, Head And Neck Cancer, Hepatocellular Carcinoma, Kidney Cancer (Renal Cell Cancer), Leiomyosarcoma, Liver Cancer, Lung Cancer, Lymphedema, Lymphoma, Metastatic Cancer, Nasopharyngeal Cancer, Parkinson's Disease, Post-Operative Pain, Prostate Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Scar and Thromboangiitis obliterans (Buerger disease).
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)
- The report reviews Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics and enlists all their major and minor projects
- The report assesses Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Overview
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Companies Involved in Therapeutics Development
AnGes Inc
F-star Biotechnology Ltd
Kringle Pharma Inc
M3 Biotechnology Inc
Minerva Biotechnologies Corp
Molecular Partners AG
ViroMed Co Ltd
YiChang Humanwell Pharmaceutical Co Ltd
Yooyoung Pharm Co Ltd
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Drug Profiles
beperminogene perplasmid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
donaperminogene seltoplasmid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FS-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy 1 to Activate HGF for Myocardial Infarction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate HGF for Critical Limb Ischemia and Chronic Post-Operative Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KP-100IT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MM-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit Hepatocyte Growth Factor for Metastatic Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MP-0250 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NDX-1017 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NK-4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SL-186 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SL-188 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YYB-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Dormant Products
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Discontinued Products
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Product Development Milestones
Featured News & Press Releases
Aug 20, 2018: Genopis builds team of experts to operate San Diego DNA production facility
Aug 01, 2018: ViroMed picks Sunyoung Kim, the founder and co-CEO, as sole chief executive
Jul 30, 2018: ViroMed announces publication on VM202’s MoA in regulating muscle atrophy
Jul 27, 2018: Last patient randomized in ViroMed’s VM202 phase III trial on PDPN
Jun 28, 2018: Drug based on ViroMed’s VM202 Technology Successfully Completes Phase II for Critical Limb Ischemia in China
Jun 15, 2018: Molecular Partners presents updated results from its ongoing Phase 2 combination study of its lead oncology drug MP0250 at EHA in Stockholm
May 30, 2018: ViroMed Announces Publication of VM202s MoA in Nerve Regeneration
May 23, 2018: VM BioPharma Presents at Pain Therapeutics Conference in UK
May 16, 2018: Molecular Partners to present final MP0250 Phase 1 data at ASCO Annual Meeting 2018
Apr 21, 2018: Molecular Partners presented preliminary results from the ongoing phase 2 study of MP0250 at the European Myeloma Network Meeting in Turin
Apr 17, 2018: ViroMed Announces Publication of VM202's MoA in Reducing Neuropathic Pain
Apr 17, 2018: ViroMeds DPN Clinical Trial Passes 70% Point in Patient Randomization
Apr 12, 2018: AARP Calls ViroMed’s VM202 “Hope” for Peripheral Neuropathy
Apr 05, 2018: Molecular Partners to present MP0250 clinical abstract at the AACR Annual Meeting 2018
Jan 22, 2018: AnGes Submits Application for Marketing Approval to PMDA for HGF gene therapy for Critical Limb Ischemia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Overview
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Companies Involved in Therapeutics Development
AnGes Inc
F-star Biotechnology Ltd
Kringle Pharma Inc
M3 Biotechnology Inc
Minerva Biotechnologies Corp
Molecular Partners AG
ViroMed Co Ltd
YiChang Humanwell Pharmaceutical Co Ltd
Yooyoung Pharm Co Ltd
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Drug Profiles
beperminogene perplasmid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
donaperminogene seltoplasmid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FS-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy 1 to Activate HGF for Myocardial Infarction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate HGF for Critical Limb Ischemia and Chronic Post-Operative Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KP-100IT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MM-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit Hepatocyte Growth Factor for Metastatic Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MP-0250 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NDX-1017 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NK-4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SL-186 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SL-188 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YYB-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Dormant Products
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Discontinued Products
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Product Development Milestones
Featured News & Press Releases
Aug 20, 2018: Genopis builds team of experts to operate San Diego DNA production facility
Aug 01, 2018: ViroMed picks Sunyoung Kim, the founder and co-CEO, as sole chief executive
Jul 30, 2018: ViroMed announces publication on VM202’s MoA in regulating muscle atrophy
Jul 27, 2018: Last patient randomized in ViroMed’s VM202 phase III trial on PDPN
Jun 28, 2018: Drug based on ViroMed’s VM202 Technology Successfully Completes Phase II for Critical Limb Ischemia in China
Jun 15, 2018: Molecular Partners presents updated results from its ongoing Phase 2 combination study of its lead oncology drug MP0250 at EHA in Stockholm
May 30, 2018: ViroMed Announces Publication of VM202s MoA in Nerve Regeneration
May 23, 2018: VM BioPharma Presents at Pain Therapeutics Conference in UK
May 16, 2018: Molecular Partners to present final MP0250 Phase 1 data at ASCO Annual Meeting 2018
Apr 21, 2018: Molecular Partners presented preliminary results from the ongoing phase 2 study of MP0250 at the European Myeloma Network Meeting in Turin
Apr 17, 2018: ViroMed Announces Publication of VM202's MoA in Reducing Neuropathic Pain
Apr 17, 2018: ViroMeds DPN Clinical Trial Passes 70% Point in Patient Randomization
Apr 12, 2018: AARP Calls ViroMed’s VM202 “Hope” for Peripheral Neuropathy
Apr 05, 2018: Molecular Partners to present MP0250 clinical abstract at the AACR Annual Meeting 2018
Jan 22, 2018: AnGes Submits Application for Marketing Approval to PMDA for HGF gene therapy for Critical Limb Ischemia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.2), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Products under Development by Companies, H2 2018 (Contd.2), H2 2018
Products under Development by Companies, H2 2018 (Contd.3), H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by AnGes Inc, H2 2018
Pipeline by F-star Biotechnology Ltd, H2 2018
Pipeline by Kringle Pharma Inc, H2 2018
Pipeline by M3 Biotechnology Inc, H2 2018
Pipeline by Minerva Biotechnologies Corp, H2 2018
Pipeline by Molecular Partners AG, H2 2018
Pipeline by ViroMed Co Ltd, H2 2018
Pipeline by YiChang Humanwell Pharmaceutical Co Ltd, H2 2018
Pipeline by Yooyoung Pharm Co Ltd, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Discontinued Products, H2 2018
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.2), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Products under Development by Companies, H2 2018 (Contd.2), H2 2018
Products under Development by Companies, H2 2018 (Contd.3), H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by AnGes Inc, H2 2018
Pipeline by F-star Biotechnology Ltd, H2 2018
Pipeline by Kringle Pharma Inc, H2 2018
Pipeline by M3 Biotechnology Inc, H2 2018
Pipeline by Minerva Biotechnologies Corp, H2 2018
Pipeline by Molecular Partners AG, H2 2018
Pipeline by ViroMed Co Ltd, H2 2018
Pipeline by YiChang Humanwell Pharmaceutical Co Ltd, H2 2018
Pipeline by Yooyoung Pharm Co Ltd, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Discontinued Products, H2 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
AnGes Inc
F-star Biotechnology Ltd
Kringle Pharma Inc
M3 Biotechnology Inc
Minerva Biotechnologies Corp
Molecular Partners AG
ViroMed Co Ltd
YiChang Humanwell Pharmaceutical Co Ltd
Yooyoung Pharm Co Ltd
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
AnGes Inc
F-star Biotechnology Ltd
Kringle Pharma Inc
M3 Biotechnology Inc
Minerva Biotechnologies Corp
Molecular Partners AG
ViroMed Co Ltd
YiChang Humanwell Pharmaceutical Co Ltd
Yooyoung Pharm Co Ltd
